From the Guidelines
The Haemophilus influenzae type b (Hib) vaccine is a conjugate vaccine that provides protection against Haemophilus influenzae type b infection, and it is recommended for infants, with three licensed vaccines available for use, including PRP-OMP (PedvaxHIB or ComVax) 1. The Hib vaccine is typically administered in a series of doses, with the first doses given at ages 2 and 4 months, and a final dose given at age 12 months or older. Key points to consider when administering the Hib vaccine include:
- If PRP-OMP is administered at ages 2 and 4 months, a dose at age 6 months is not required 1.
- DTaP/Hib combination products should not be used for primary vaccination in infants at ages 2-6 months but can be used as boosters after any Hib vaccine 1. The Hib vaccine works by introducing conjugated Haemophilus influenzae type b particles that stimulate the immune system to produce protective antibodies without causing disease. Side effects are generally mild and may include soreness at the injection site, headache, or fatigue. The vaccine is highly effective, with a significant reduction in Haemophilus influenzae type b infections in vaccinated populations 1.
From the Research
Haemophilus influenzae type b (Hib) Vaccine
There are no research papers to assist in answering this question, as the provided studies focus on influenza vaccines and not the Haemophilus influenzae type b (Hib) vaccine.
- The studies provided discuss various aspects of influenza vaccines, including their efficacy, safety, and potential for broad-spectrum protection 2, 3, 4, 5, 6.
- They explore the use of recombinant hemagglutinin, nanoparticle vaccines, and conserved hemagglutinin stalk domain as potential targets for universal influenza vaccine development.
- However, none of the studies mention the Haemophilus influenzae type b (Hib) vaccine, which is a separate and distinct vaccine targeting a different pathogen.